Doxecitine and Doxribtimine Combination Therapy: The First Treatment for Thymidine Kinase 2 Deficiency

Neurologist Michio Hirano, MD, provides an overview of thymidine kinase 2 deficiency, discussing its underlying biology, clinical presentation, and natural history before the advent of disease-modifying therapy.

Episode 2 traces the decades of research, clinical development, and pivotal findings that culminated in the first approved therapy for thymidine kinase 2 deficiency.

Michio Hirano, MD, explains the unconventional clinical development strategy behind doxecitine and doxribtimine, highlighting why an open label approach and historical controls were necessary in TK2 deficiency.

Episode 4 of this Special Report covers the key efficacy findings supporting doxecitine and doxribtimine, highlighting how improvements in survival, motor milestones, respiratory function, and swallowing translate into meaningful clinical benefits for patients with TK2 deficiency.

Neurologist Michio Hirano, MD, reviews the safety profile of doxecitine and doxribtimine, discussing common adverse events, dose management strategies, and practical considerations for monitoring patients with TK2 deficiency.

The final episode covers the practical considerations of implementing doxecitine and doxribtimine in clinical practice, emphasizing early diagnosis, multidisciplinary care, and the next frontier of TK2 deficiency research.